You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tislelizumab

Showing 51 - 75 of 200
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Hepatocellular Carcinoma Trial in Shanghai (Tislelizumab, lenvatinib, US/CT-guided Percutaneous Cryoablation)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Tislelizumab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 8, 2022

Triple Negative Breast Cancer Trial (Ociperlimab, Tislelizumab, Paclitaxel)

Not yet recruiting
  • Triple Negative Breast Cancer
  • (no location specified)
Mar 30, 2023

Nasopharyngeal Carcinoma Trial in Beijing (Tislelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Tislelizumab
  • Beijing, Beijing, China
    National Cancer Center /National Clinical Research Center for Ca
Jul 4, 2022

Uterine Cervical Tumors Trial in Nanning (Tislelizumab, DDP synchronous with radiotherapy)

Recruiting
  • Uterine Cervical Neoplasms
  • Tislelizumab
  • DDP synchronous with radiotherapy
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Oct 19, 2022

Recurrent Hepatocellular Carcinoma Trial in Guangzhou (Tislelizumab, Tislelizumab combined with Levatinib)

Recruiting
  • Recurrent Hepatocellular Carcinoma
  • Tislelizumab
  • Tislelizumab combined with Levatinib
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Mar 31, 2022

Carcinoma, Hepatocellular, Liver Cell Carcinoma Trial in New Brunswick (Tislelizumab)

Recruiting
  • Carcinoma, Hepatocellular
  • Liver Cell Carcinoma
  • Tislelizumab
  • New Brunswick, New Jersey
  • +1 more
Sep 27, 2022

Immunotherapy Esophagus Cancer Trial (Tislelizumab, Albumin paclitaxel, Nedaplatin)

Not yet recruiting
  • Immunotherapy Esophagus Cancer
  • Tislelizumab
  • +3 more
  • (no location specified)
Aug 24, 2022

Extensive Stage Small Cell Lung Cancer Trial in France ([177Lu]Lu-DOTA-TATE, Tislelizumab, [68Ga]Ga-DOTA-TATE)

Recruiting
  • Extensive Stage Small Cell Lung Cancer
  • Lille, France
  • +6 more
Jan 23, 2023

Stage III NSCLC Trial in Guangzhou (Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy)

Recruiting
  • Stage III Non-small Cell Lung Cancer
  • Neoadjuvant chemo-immunotherapy
  • +5 more
  • Guangzhou, China
    Sun Yat-sen University
Jul 19, 2022

Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation Trial in Nanjing (Tislelizumab, Paclitaxel, Carboplatin)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Tislelizumab
  • +3 more
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Institute & Hospital
May 24, 2022

Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma Trial (BGB-A445, Tislelizumab)

Not yet recruiting
  • Urothelial Carcinoma
  • +2 more
  • (no location specified)
Dec 15, 2022

Cervical Cancer Trial in Nanning (tislelizumab, concurrent chemoradiotherapy)

Not yet recruiting
  • Cervical Cancer
  • tislelizumab
  • concurrent chemoradiotherapy
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Aug 22, 2022

NSCLC, Metastatic NSCLC Trial (Tislelizumab, BGB-A445, LBL-007)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Metastatic Non-small Cell Lung Cancer
  • Tislelizumab
  • +7 more
  • (no location specified)
Dec 14, 2022

Head and Neck Squamous Cell Carcinoma Trial (Nab-paclitaxel, Cisplatin, Tislelizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Aug 23, 2022

Lymphoma Trial (Tislelizumab)

Not yet recruiting
  • Lymphoma
  • Tislelizumab
  • (no location specified)
Jul 28, 2022

NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 17, 2023

Gastric Cancer Trial in Shanghai (PLD, Oxaliplatin, Capecitabine)

Recruiting
  • Gastric Cancer
  • Shanghai, China
    Shanghai General Hospital
Sep 7, 2022

Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma Trial in Nanjing (Tislelizumab, 5-FU, cis Platinum)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Locally Advanced Carcinoma
  • Tislelizumab
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Jul 19, 2022

Colorectal Cancer Trial in Shanghai (HAIC, Fruquintinib, Tislelizumab)

Recruiting
  • Colorectal Cancer
  • HAIC
  • +5 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 15, 2022

Hepatocellular Carcinoma by BCLC Stage Trial in Rennes (Tislelizumab)

Not yet recruiting
  • Hepatocellular Carcinoma by BCLC Stage
  • Tislelizumab
  • Rennes, France
    Centre Eugene Marquis
Jan 16, 2023

Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor Trial in Australia, France, United States (BGB-A3055, Tislelizumab)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • Iowa City, Iowa
  • +7 more
Jul 5, 2023

Immunotherapy, Colorectal Cancer Trial in Fuzhou (Tislelizumab, bevacizumab, TAS-102)

Recruiting
  • Immunotherapy
  • Colorectal Cancer
  • Tislelizumab
  • +2 more
  • Fuzhou, Fujian, China
  • +1 more
Jul 20, 2022

Lung Cancer, Small Cell Trial in Hangzhou (Tislelizumab, Sitravatinib)

Recruiting
  • Lung Cancer, Small Cell
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 13, 2022

Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma Trial in China (Tislelizumab, Albumin-Bound Paclitaxel,

Recruiting
  • Oral Squamous Cell Carcinoma
  • Oropharyngeal Squamous Cell Carcinoma
  • Tislelizumab
  • +2 more
  • Beijing, Beijing, China
  • +13 more
Aug 22, 2023

Urothelial Carcinoma Bladder, PD-1 Inhibitor Trial in Shanghai (Tislelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Urothelial Carcinoma Bladder
  • PD-1 Inhibitor
  • Tislelizumab
  • +2 more
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 15, 2022